$2.95
1.72% yesterday
Nasdaq, May 20, 10:09 pm CET
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Solid Biosciences Inc. Stock price

$2.95
-0.08 2.64% 1M
-2.01 40.52% 6M
-1.05 26.25% YTD
-6.17 67.65% 1Y
-5.24 63.97% 3Y
-44.45 93.78% 5Y
-336.35 99.13% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 1.72%
ISIN
US83422E1055
Symbol
SLDB
Sector
Industry

Key metrics

Market capitalization $228.67m
Enterprise Value $-54.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.51
P/B ratio (TTM) P/B ratio 0.78
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.92m
Free Cash Flow (TTM) Free Cash Flow $-107.30m
Cash position $306.92m
EPS (TTM) EPS $-2.99
P/E forward negative
Short interest 10.89%
Show more

Is Solid Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Solid Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Solid Biosciences Inc. forecast:

Buy
100%

Financial data from Solid Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 2.54 2.54
15% 15%
-
-2.54 -2.54
15% 15%
-
- Selling and Administrative Expenses 29 29
23% 23%
-
- Research and Development Expense 108 108
53% 53%
-
-140 -140
45% 45%
-
- Depreciation and Amortization 2.54 2.54
15% 15%
-
EBIT (Operating Income) EBIT -143 -143
44% 44%
-
Net Profit -140 -140
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about Solid Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Solid Biosciences Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cas...
Neutral
GlobeNewsWire
19 days ago
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees.
Neutral
GlobeNewsWire
21 days ago
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET.
More Solid Biosciences Inc. News

Company Profile

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Alexander Cumbo
Employees 100
Founded 2013
Website www.solidbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today